Biomaterial applications in cardiovascular tissue repair and regeneration

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 8, 2012, Pages 1039-1049

  Lam, Mai T ^a   Wu, Joseph C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomaterials; cardiac repair; decellularized tissues; extracellular matrix; metals; polymers; regeneration; stem cells; tissue reconstruction

Indexed keywords

ALGINIC ACID; BIOMATERIAL; CHITOSAN; CHROMIUM; COBALT; COLLAGEN; COLLAGEN GEL; COPOLYMER; EXPANDED POLYTETRAFLUOROETHYLENE; FIBRIN; MATRIGEL; METAL; NANOFIBER; NICKEL; NITINOL; PLATINUM; POLITEF; POLYETHYLENE TEREPHTHALATE; POLYMER; POLYURETHAN; SILICONE; TITANIUM; UNCLASSIFIED DRUG; WARFARIN;

ARTIFICIAL HEART; ATS VALVE; BLOOD CLOTTING; BLOOD VESSEL GRAFT; CARDIOVASCULAR TISSUE REGENERATION; CARDIOVASCULAR TISSUE REPAIR; CERAMICS; CORONARY STENT; DACRON VASCULAR PROSTHESIS; EXTRACELLULAR MATRIX; FOREIGN BODY REACTION; GRAFT PATENCY; HEART INFARCTION; HEART VALVE BIOPROSTHESIS; HEART VALVE PROSTHESIS; HUMAN; NONHUMAN; PERICARDIUM; POLYMERIZATION; PROSTHETIC VALVE THROMBOSIS; REVIEW; SMALL INTESTINE MUCOSA; SUBMUCOSA; TISSUE ENGINEERING; TISSUE REGENERATION; TISSUE REPAIR;

ANIMALS; BIOCOMPATIBLE MATERIALS; BIOPROSTHESIS; CARDIOLOGY; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HUMANS; REGENERATION; REGENERATIVE MEDICINE; TISSUE ENGINEERING;

EID: 84867035933     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.99     Document Type: Review

References (100)

1. Roger VL, Go AS, Lloyd-Jones DM et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 125(1), e2-e220 (2012).
2. Aumsuwan N, Ye SH, Wagner WR, Urban MW. Covalent attachment of multilayers on poly(tetrafluoroethylene) surfaces. Langmuir 27(17), 11106-11110 (2011).
3. Saha SP, Muluk S, Schenk W 3rd et al. Use of fibrin sealant as a hemostatic agent in expanded polytetrafluoroethylene graft placement surgery. Ann. Vasc. Surg. 25(6), 813-822 (2011).
4. Wang S, Gupta AS, Sagnella S, Barendt PM, Kottke-Marchant K, Marchant RE. Biomimetic fluorocarbon surfactant polymers reduce platelet adhesion on PTFE/ePTFE surfaces. J. Biomater. Sci. Polym. Ed. 20(5-6), 619-635 (2009).
5. Yashiro B, Shoda M, Tomizawa Y, Manaka T, Hagiwara N. Long-term results of a cardiovascular implantable electronic device wrapped with an expanded polytetrafluoroethylene sheet. J. Artif. Organs doi:10.1007/s10047-012-0634-8 (2012) (Epub ahead of print).
6. Barozzi L, Brizard CP, Galati JC, Konstantinov IE, Bohuta L, d'Udekem Y. Side-to-side aorto-GoreTex central shunt warrants central shunt patency and pulmonary arteries growth. Ann. Thorac. Surg. 92(4), 1476-1482 (2011).
7. Verbelen TO, Famaey N, Gewillig M, Rega FR, Meyns B. Off-label use of stretchable polytetrafluoroethylene: overexpansion of synthetic shunts. Int. J. Artif. Organs 33(5), 263-270 (2010).
8. Doble M, Makadia N, Pavithran S, Kumar RS. Analysis of explanted ePTFE cardiovascular grafts (modified BT shunt). Biomed. Mater. 3(3), 034118 (2008).
9. Oda T, Hoashi T, Kagisaki K, Shiraishi I, Yagihara T, Ichikawa H. Alternative to pulmonary allograft for reconstruction of right ventricular outflow tract in small patients undergoing the Ross procedure. Eur. J. Cardiothorac. Surg. 42(2), 226-232 (2012).
10. Miyazaki T, Yamagishi M, Nakashima A et al. Expanded polytetrafluoroethylene valved conduit and patch with bulging sinuses in right ventricular outflow tract reconstruction. J. Thorac. Cardiovasc. Surg. 134(2), 327-332 (2007).
11. Miyazaki T, Yamagishi M, Maeda Y et al. Expanded polytetrafluoroethylene conduits and patches with bulging sinuses and fan-shaped valves in right ventricular outflow tract reconstruction: multicenter study in Japan. J. Thorac. Cardiovasc. Surg. 142(5), 1122-1129 (2011).
12. Ando M, Takahashi Y. Ten-year experience with handmade trileaflet polytetrafluoroethylene valved conduit used for pulmonary reconstruction. J. Thorac. Cardiovasc. Surg. 137(1), 124-131 (2009).
13. Kudo FA, Nishibe T, Miyazaki K, Flores J, Yasuda K. Albumin-coated knitted Dacron aortic prosthses. Study of postoperative inflammatory reactions. Int. Angiol. 21(3), 214-217 (2002).
14. Nagano N, Cartier R, Zigras T, Mongrain R, Leask RL. Mechanical properties and microscopic findings of a Dacron graft explanted 27 years after coarctation repair. J. Thorac. Cardiovasc. Surg. 134(6), 1577-1578 (2007).
15. Shayani V, Newman KD, Dichek DA. Optimization of recombinant t-PA secretion from seeded vascular grafts. J. Surg. Res. 57(4), 495-504 (1994).
16. Jensen N, Lindblad B, Bergqvist D. Endothelial cell seeded dacron aortobifurcated grafts: platelet deposition and long-term follow-up. J. Cardiovasc. Surg. (Torino) 35(5), 425-429 (1994).
17. Roll S, Müller-Nordhorn J, Keil T et al. Dacron vs. PTFE as bypass materials in peripheral vascular surgery - systematic review and meta-analysis. BMC Surg. 8, 22 (2008).
18. Maya ID, Weatherspoon J, Young CJ, Barker J, Allon M. Increased risk of infection associated with polyurethane dialysis grafts. Semin. Dial. 20(6), 616-620 (2007).
19. Kütting M, Roggenkamp J, Urban U, Schmitz-Rode T, Steinseifer U. Polyurethane heart valves: past, present and future. Expert Rev. Med. Devices 8(2), 227-233 (2011).
20. Silvetti MS, Drago F, Ravà L. Long-term outcome of transvenous bipolar atrial leads implanted in children and young adults with congenital heart disease. Europace 14(7), 1002-1007 (2012).
21. Johnson WB, Braly A, Cobian K et al. Effect of insulation material in aging pacing leads: comparison of impedance and other electricals: time-dependent pacemaker insulation changes. Pacing Clin. Electrophysiol. 35(1), 51-57 (2012).
22. Parrag IC, Zandstra PW, Woodhouse KA. Fiber alignment and coculture with fibroblasts improves the differentiated phenotype of murine embryonic stem cell-derived cardiomyocytes for cardiac tissue engineering. Biotechnol. Bioeng. 109(3), 813-822 (2012).
23. Wang PY, Yu J, Lin JH, Tsai WB. Modulation of alignment, elongation and contraction of cardiomyocytes through a combination of nanotopography and rigidity of substrates. Acta Biomater. 7(9), 3285-3293 (2011).
24. Stachelek SJ, Alferiev I, Fulmer J, Ischiropoulos H, Levy RJ. Biological stability of polyurethane modified with covalent attachment of di-tert-butylphenol. J. Biomed. Mater. Res. A 82(4), 1004-1011 (2007).
25. Koh AS, Choi LM, Sim LL et al. Comparing the use of cobalt chromium stents to stainless steel stents in primary percutaneous coronary intervention for acute myocardial infarction: a prospective registry. Acute Card. Care 13(4), 219-222 (2011).
26. O'Brien BJ, Stinson JS, Larsen SR, Eppihimer MJ, Carroll WM. A platinum- chromium steel for cardiovascular stents. Biomaterials 31(14), 3755-3761 (2010).
27. Rigatelli G, Cardaioli P, Giordan M et al. Nickel allergy in interatrial shunt device-based closure patients. Congenit. Heart Dis. 2(6), 416-420 (2007).
28. van Putte BP, Ozturk S, Siddiqi S, Schepens MA, Heijmen RH, Morshuis WJ. Early and late outcome after aortic root replacement with a mechanical valve prosthesis in a series of 528 patients. Ann. Thorac. Surg. 93(2), 503-509 (2012).
29. Akhtar RP, Abid AR, Zafar H, Khan JS. Anticoagulation in patients following prosthetic heart valve replacement. Ann. Thorac. Cardiovasc. Surg. 15(1), 10-17 (2009).
30. Dalmau MJ, González-Santos JM, Blázquez JA et al. Hemodynamic performance of the Medtronic Mosaic and Perimount Magna aortic bioprostheses: five-year results of a prospectively randomized study. Eur. J. Cardiothorac. Surg. 39(6), 844-852; discussion 852 (2011).
31. Hodges AM, Lyster H, McDermott A et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 93(6), 650-656 (2012).
32. Byrne GW, McGregor CG. Cardiac xenotransplantation: progress and challenges. Curr. Opin. Organ Transplant. 17(2), 148-154 (2012).
33. Badylak S, Obermiller J, Geddes L, Matheny R. Extracellular matrix for myocardial repair. Heart Surg. Forum 6(2), e20-e26 (2003).
34. Badylak SF. The extracellular matrix as a biologic scaffold material. Biomaterials 28(25), 3587-3593 (2007).
35. Boyd WD, Johnson WE 3rd, Sultan PK, Deering TF, Matheny RG. Pericardial reconstruction using an extracellular matrix implant correlates with reduced risk of postoperative atrial fibrillation in coronary artery bypass surgery patients. Heart Surg. Forum 13(5), e311-e316 (2010).
36. Fallon A, Goodchild T, Wang R, Matheny RG. Remodeling of extracellular matrix patch used for carotid artery repair. J. Surg. Res. 175(1), e25-e34 (2012).
37. Zantop T, Gilbert TW, Yoder MC, Badylak SF. Extracellular matrix scaffolds are repopulated by bone marrow-derived cells in a mouse model of achilles tendon reconstruction. J. Orthop. Res. 24(6), 1299-1309 (2006).
38. Zhao ZQ, Puskas JD, Xu D et al. Improvement in cardiac function with small intestine extracellular matrix is associated with recruitment of c-Kit cells, myofibroblasts, and macrophages after myocardial infarction. J. Am. Coll. Cardiol. 55(12), 1250-1261 (2010).
39. Crapo PM, Wang Y. Small intestinal submucosa gel as a potential scaffolding material for cardiac tissue engineering. Acta Biomater. 6(6), 2091-2096 (2010).
40. Tan MY, Zhi W, Wei RQ et al. Repair of infarcted myocardium using mesenchymal stem cell seeded small intestinal submucosa in rabbits. Biomaterials 30(19), 3234-3240 (2009).
41. Inoue H, Iguro Y, Matsumoto H, Ueno M, Higashi A, Sakata R. Right hemireconstruction of the left atrium using two equine pericardial patches for recurrent malignant fibrous histiocytoma: report of a case. Surg. Today 39(8), 710-712 (2009).
42. Shinn SH, Sung K, Park PW et al. Results of annular reconstruction with a pericardial patch in active infective endoarditis. J. Heart Valve Dis. 18(3), 315-320 (2009).
43. ASM International. Materials and Coatings for Medical Devices: Cardiovascular. ASM International, OH, USA, 12-18 (2009).
44. Goissis G, Giglioti Ade F, Braile DM. Preparation and characterization of an acellular bovine pericardium intended for manufacture of valve bioprostheses. Artif. Organs 35(5), 484-489 (2011).
45. Braile MC, Carnevalli NC, Goissis G, Ramirez VA, Braile DM. In vitro properties and performance of glutaraldehydecrosslinked bovine pericardial bioprostheses treated with glutamic acid. Artif. Organs 35(5), 497-501 (2011).
46. Sinha P, Zurakowski D, Kumar TK, He D, Rossi C, Jonas RA. Effects of glutaraldehyde concentration, pretreatment time, and type of tissue (porcine versus bovine) on postimplantation calcification. J. Thorac. Cardiovasc. Surg. 143(1), 224-227 (2012).
47. Guldner NW, Bastian F, Weigel G et al. Nanocoating with titanium reduces iC3b- and granulocyte-activating immune response against glutaraldehyde-fixed bovine pericardium: a new technique to improve biologic heart valve prosthesis durability?. J. Thorac. Cardiovasc. Surg. 143(5), 1152-1159 (2012).
48. Braga-Vilela AS, Pimentel ER, Marangoni S, Toyama MH, de Campos Vidal B. Extracellular matrix of porcine pericardium: biochemistry and collagen architecture. J. Membr. Biol. 221(1), 15-25 (2008).
49. Liao K, Seifter E, Hoffman D, Yellin EL, Frater RW. Bovine pericardium versus porcine aortic valve: comparison of tissue biological properties as prosthetic valves. Artif. Organs 16(4), 361-365 (1992).
50. Chambers JB, Rajani R, Parkin D et al. Bovine pericardial versus porcine stented replacement aortic valves: early results of a randomized comparison of the Perimount and the Mosaic valves. J. Thorac. Cardiovasc. Surg. 136(5), 1142-1148 (2008).
51. Eikelboom JW, Hart RG. Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. Am. J. Hematol. 87(Suppl. 1), S100-S107 (2012).
52. McGregor CG, Carpentier A, Lila N, Logan JS, Byrne GW. Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valves. J. Thorac. Cardiovasc. Surg. 141(1), 269-275 (2011).
53. Law KB, Phillips KR, Butany J. Pulmonary valve-in-valve implants: how long do they prolong reintervention and what causes them to fail?. Cardiovasc. Pathol. doi:10.1016/j.carpath.2012.02.010 (2012) (Epub ahead of print).
54. Weber A, Noureddine H, Englberger L et al. Ten-year comparison of pericardial tissue valves versus mechanical prostheses for aortic valve replacement in patients younger than 60 years of age. J. Thorac. Cardiovasc. Surg. doi:10.1016/j.jtcvs.2012.01.024 (2012) (Epub ahead of print).
55. Chikwe J, Filsoufi F, Carpentier AF. Prosthetic valve selection for middle-aged patients with aortic stenosis. Nat. Rev. Cardiol. 7(12), 711-719 (2010).
56. Segers VF, Lee RT. Biomaterials to enhance stem cell function in the heart. Circ. Res. 109(8), 910-922 (2011).
57. Rane AA, Christman KL. Biomaterials for the treatment of myocardial infarction: a 5-year update. J. Am. Coll. Cardiol. 58(25), 2615-2629 (2011).
58. Venugopal JR, Prabhakaran MP, Mukherjee S, Ravichandran R, Dan K, Ramakrishna S. Biomaterial strategies for alleviation of myocardial infarction. J. R. Soc. Interface 9(66), 1-19 (2012).
59. Ruvinov E, Harel-Adar T, Cohen S. Bioengineering the infarcted heart by applying bio-inspired materials. J. Cardiovasc. Transl. Res. 4(5), 559-574 (2011).
60. Leor J, Tuvia S, Guetta V et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J. Am. Coll. Cardiol. 54(11), 1014-1023 (2009).
61. Kin H, Nakajima T, Okabayashi H. Experimental study on effective application of fibrin glue. Gen. Thorac. Cardiovasc. Surg. 60(3), 140-144 (2012).
62. Wu X, Ren J, Li J. Fibrin glue as the cell-delivery vehicle for mesenchymal stromal cells in regenerative medicine. Cytotherapy 14(5), 555-562 (2012).
63. Liu Y, Cheng XJ, Dang QF et al. Preparation and evaluation of oleoyl- carboxymethy-chitosan (OCMCS) nanoparticles as oral protein carriers. J. Mater. Sci. Mater. Med. 23(2), 375-384 (2012).
64. Liu Z, Wang H, Wang Y et al. The influence of chitosan hydrogel on stem cell engraftment, survival and homing in the ischemic myocardial microenvironment. Biomaterials 33(11), 3093-3106 (2012).
65. Gupta V, Werdenberg JA, Blevins TL, Grande-Allen KJ. Synthesis of glycosaminoglycans in differently loaded regions of collagen gels seeded with valvular interstitial cells. Tissue Eng. 13(1), 41-49 (2007).
66. Frederick JR, Fitzpatrick JR 3rd, McCormick RC et al. Stromal cell-derived factor-1? activation of tissue-engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovasculogenesis. Circulation 122(Suppl. 11), S107-S117 (2010).
67. Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics 10(9), 1886-1890 (2010).
68. Kim JH, Jung Y, Kim SH et al. The enhancement of mature vessel formation and cardiac function in infarcted hearts using dual growth factor delivery with self-assembling peptides. Biomaterials 32(26), 6080-6088 (2011).
69. Nguyen PK, Lan F, Wang Y, Wu JC. Imaging: guiding the clinical translation of cardiac stem cell therapy. Circ. Res. 109(8), 962-979 (2011).
70. Apte SS, Paul A, Prakash S, Shum-Tim D. Current developments in the tissue engineering of autologous heart valves: moving towards clinical use. Future Cardiol. 7(1), 77-97 (2011).
71. Sacks MS, Schoen FJ, Mayer JE. Bioengineering challenges for heart valve tissue engineering. Annu. Rev. Biomed. Eng. 11, 289-313 (2009).
72. Dainese L, Guarino A, Burba I et al. Heart valve engineering: decellularized aortic homograft seeded with human cardiac stromal cells. J. Heart Valve Dis. 21(1), 125-134 (2012).
73. Cigliano A, Gandaglia A, Lepedda AJ et al. Fine structure of glycosaminoglycans from fresh and decellularized porcine cardiac valves and pericardium. Biochem. Res. Int. 2012, 979351 (2012).
74. Robinson PS, Johnson SL, Evans MC, Barocas VH, Tranquillo RT. Functional tissue-engineered valves from cell-remodeled fibrin with commissural alignment of cell-produced collagen. Tissue Eng. Part A 14(1), 83-95 (2008).
75. Perri G, Polito A, Esposito C et al. Early and late failure of tissue-engineered pulmonary valve conduits used for right ventricular outflow tract reconstruction in patients with congenital heart disease. Eur. J. Cardiothorac. Surg. 41(6), 1320-1325 (2012).
76. Dohmen PM, Lembcke A, Holinski S, Pruss A, Konertz W. Ten years of clinicalresults with a tissue-engineered pulmonary valve. Ann. Thorac. Surg. 92(4), 1308-1314 (2011).
77. Konertz W, Angeli E, Tarusinov G et al. Right ventricular outflow tract reconstruction with decellularized porcine xenografts in patients with congenital heart disease. J. Heart Valve Dis. 20(3), 341-347 (2011).
78. Feinberg AW, Alford PW, Jin H et al. Controlling the contractile strength of engineered cardiac muscle by hierarchal tissue architecture. Biomaterials 33(23), 5732-5741 (2012).
79. Cashman TJ, Gouon-Evans V, Costa KD. Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms. Stem Cell Rev. doi:10.1007/ s12015-012-9375-6 (2012) (Epub ahead of print).
80. Karam JP, Muscari C, Montero-Menei CN. Combining adult stem cells and polymeric devices for tissue engineering in infarcted myocardium. Biomaterials 33(23), 5683-5695 (2012).
81. Wang B, Tedder ME, Perez CE et al. Structural and biomechanical characterizations of porcine myocardial extracellular matrix. J. Mater. Sci. Mater. Med. 23(8), 1835-1847 (2012).
82. Eschenhagen T, Eder A, Vollert I, Hansen A. Physiological aspects of cardiac tissue engineering. Am. J. Physiol. Heart Circ. Physiol. 303(2), H133-H143 (2012).
83. Ravichandran R, Venugopal JR, Sundarrajan S, Mukherjee S, Sridhar R, Ramakrishna S. Expression of cardiac proteins in neonatal cardiomyocytes on PGS/fibrinogen core/shell substrate for cardiac tissue engineering. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.04.045 (2012) (Epub ahead of print).
84. Haraguchi Y, Shimizu T, Sasagawa T et al. Fabrication of functional three-dimensional tissues by stacking cell sheets in vitro. Nat. Protoc. 7(5), 850-858 (2012).
85. Chachques JC, Trainini JC, Lago N et al. Myocardial assistance by grafting a new bioartificial upgraded myocardium (MAGNUM clinical trial): one year follow-up. Cell Transplant. 16(9), 927-934 (2007).
86. Shinoka T, Breuer C. Tissue-engineered blood vessels in pediatric cardiac surgery. Yale J. Biol. Med. 81(4), 161-166 (2008).
87. Pok S, Jacot JG. Biomaterials advances in patches for congenital heart defect repair. J. Cardiovasc. Transl. Res. 4(5), 646-654 (2011).
88. Place ES, George JH, Williams CK, Stevens MM. Synthetic polymer scaffolds for tissue engineering. Chem. Soc. Rev. 38(4), 1139-1151 (2009).
89. Tous E, Weber HM, Lee MH et al. Tunable hydrogel-microsphere composites that modulate local inflammation and collagen bulking. Acta Biomater. 8(9), 3218-3227 (2012).
90. Chiu LL, Janic K, Radisic M. Engineering of oriented myocardium on threedimensional micropatterned collagen-chitosan hydrogel. Int. J. Artif. Organs 35(4), 237-250 (2012).
91. Deng C, Vulesevic B, Ellis C, Korbutt GS, Suuronen EJ. Vascularization of collagen-chitosan scaffolds with circulating progenitor cells as potential site for islet transplantation. J. Control. Release 152(Suppl. 1), e196-e198 (2011).
92. Wang Q, McGoron AJ, Pinchuk L, Schoephoerster RT. A novel small animal model for biocompatibility assessment of polymeric materials for use in prosthetic heart valves. J. Biomed. Mater. Res. A 93(2), 442-453 (2010).
93. Laflamme MA, Chen KY, Naumova AV et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25(9), 1015-1024 (2007).
94. Simpson D, Liu H, Fan TH, Nerem R, Dudley SC Jr. A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling. Stem Cells 25(9), 2350-2357 (2007).
95. Pozzobon M, Bollini S, Iop L et al. Human bone marrow-derived CD133(+) cells delivered to a collagen patch on cryoinjured rat heart promote angiogenesis and arteriogenesis. Cell Transplant. 19(10), 1247-1260 (2010).
96. Spadaccio C, Chello M, Trombetta M, Rainer A, Toyoda Y, Genovese JA. Drug releasing systems in cardiovascular tissue engineering. J. Cell. Mol. Med. 13(3), 422-439 (2009).
97. Zhang G, Suggs LJ. Matrices and scaffolds for drug delivery in vascular tissue engineering. Adv. Drug Deliv. Rev. 59(4-5), 360-373 (2007).
98. Polizzotti BD, Arab S, Kühn B. Intrapericardial delivery of gelfoam enables the targeted delivery of periostin peptide after myocardial infarction by inducing fibrin clot formation. PLoS ONE 7(5), e36788 (2012).
99. Chiu LL, Radisic M. Controlled release of thymosin b4 using collagen-chitosan composite hydrogels promotes epicardial cell migration and angiogenesis. J. Control. Release 155(3), 376-385 (2011).
100. Zeng F, Lee H, Allen C. Epidermal growth factor-conjugated poly(ethylene glycol)- block-poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. Bioconjug. Chem. 17(2), 399-409 (2006).